Furthermore, IL‐15 or pharmacologically enhanced IL‐15 superagonists like N‐803 are the subject of clinical trials with more than 50 ongoing studies of cancer of which at least four specifically focus on PDAC (NCT03329248, NCT03387098, NCT03586869 and NCT03136406). This evidence concerns the gene IL15 and cancer.